TRIL Trillium Therapeutics Inc.
Trillium Therapeutics Inc. (TRIL) is expected to report earnings on March 17, 2022, after the market close.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Trillium Therapeutics Inc.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties.
Charts powered in part by Lightweight Charts™ by TradingView.